Springboks wary of new-look All Blacks in Baltimore test
South Africa captain Siya Kolisi said the Springboks will be ready to face a much-changed All Blacks side as the world champions look to wrap up a...
09/02/2026 12:00
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VH...
09/02/2026 12:00
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenviron...
Around 20 injured as train derails in northwest France: transport minister
About 20 people were injured when a regional train derailed in northwest France on Friday, Transport Minister Philippe Tabarot said on X, stressing...
09/02/2026 12:00
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. This press relea...
Zelensky in fresh talks with US envoys: Ukraine official
Washington's envoys have brought new proposals on ending the war with Russia to Kyiv and President Volodymyr Zelensky is meeting them again in a trio format, a senior Ukrainian...
Sabalenka books US Open quarter-final clash with Noskova
Two-time defending champion Aryna Sabalenka subdued American Taylor Townsend in straight sets on Sunday to book a US Open quarter-final clash...
Amazon cargo plane overshoots Miami runway, hits vehicles, catches fire
An Amazon cargo plane overshot a runway as it landed Sunday in Miami, crashing into vehicles and...
Noskova edges Kostyuk to reach US Open quarter-finals
Wimbledon champion Linda Noskova reached the quarter-finals of the US Open on Sunday, edging Ukraine's Marta...
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®
Mainstay Medical Holdings plc today announced the publication of the two-year assessment results from the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show continued improvements in back pain-related disability, pain and quality of life in the ReActiv8 treatment group, and improvements after one year of ReActiv8 therapy in the crossover group that were indistinguishable from the improvements shown by the treatment group at their one-year assessment. The results were published inThe Spine Journal...
Anglais